STAGE IV UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Clinical trials for STAGE IV UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…
Matched conditions: STAGE IV UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:06 UTC
-
New drug cocktails aim to stall endometrial Cancer's return
Disease control OngoingThis study tests several drug combinations in women whose endometrial cancer has returned or not responded to treatment. The goal is to see if these combinations can slow or stop cancer growth better than current options. About 288 women are taking part, receiving different drugs…
Matched conditions: STAGE IV UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:51 UTC
-
New combo therapy targets hard-to-treat HER2 cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…
Matched conditions: STAGE IV UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Immunotherapy plus chemo shows promise for tough endometrial cancers
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without the cancer growing. About 813 participants with stage III, IV, or recurrent di…
Matched conditions: STAGE IV UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 05, 2026 11:54 UTC